Lin Yu-Chin, Tsai Chung-Hsin, Wu Jia-Shing, Huang Chiun-Sheng, Kuo Sung-Hsin, Lin Chung-Wu, Cheng Ann-Lii
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Leuk Lymphoma. 2009 Jun;50(6):918-24. doi: 10.1080/10428190902777475.
Breast lymphoma is a rare form of non-Hodgkin lymphoma (NHL). However, its clinicopathologic features, treatment, patterns of failure and prognosis remains unclear. We reviewed the clinicopathologic features, treatment variables, failure patterns and the clinical outcome of all cases of breast NHL diagnosed in three institutions in Taiwan between 1984 and 2006. The diagnosis, based on the criteria proposed by Wiseman and Liao, was primary breast lymphoma (PBL) in 23 patients and secondary breast lymphoma (SBL) in 19. Diffuse large B-cell lymphoma was the predominant histological type of both. Among patients with PBL, 18 received chemotherapy and radiotherapy, 3 received chemotherapy alone and 2 received radiotherapy alone. In contrast, all 19 patients with SBL received chemotherapy alone. At a median follow-up of 4.4 years, patients with PBL had a significantly better 5-year event-free survival and overall survival. The contralateral breast was the predominant site of recurrence for patients with PBL. In multivariate analyses, young age and stage IIE disease were significantly associated with poorer prognosis of PBL. Our results indicate combined modality treatment results in a favourable outcome for patients with PBL. Further investigation of underlying mechanisms of young age- and stage IIE disease-related poor prognosis in patients with PBL is needed.
乳腺淋巴瘤是一种罕见的非霍奇金淋巴瘤(NHL)。然而,其临床病理特征、治疗、复发模式及预后仍不明确。我们回顾了1984年至2006年间台湾三家机构诊断的所有乳腺NHL病例的临床病理特征、治疗变量、复发模式及临床结局。根据Wiseman和Liao提出的标准,诊断为原发性乳腺淋巴瘤(PBL)23例,继发性乳腺淋巴瘤(SBL)19例。弥漫性大B细胞淋巴瘤是两者的主要组织学类型。PBL患者中,18例接受了化疗和放疗,3例仅接受化疗,2例仅接受放疗。相比之下,19例SBL患者均仅接受化疗。中位随访4.4年时,PBL患者的5年无事件生存率和总生存率显著更好。对侧乳腺是PBL患者的主要复发部位。多因素分析显示,年轻和IIE期疾病与PBL患者预后较差显著相关。我们的结果表明,综合治疗模式可为PBL患者带来良好结局。需要进一步研究PBL患者中年轻和IIE期疾病相关预后不良的潜在机制。